Douglas Vaughan, MD

Original Contribution

Release and Elimination of Soluble Vasoactive Factors during Percutaneous Coronary Intervention of Saphenous Vein Grafts: Analys

08/01/2008

David X. Zhao , MD;

Douglas Vaughan , MD;

Joseph G. Salloum , MD;

Carter Tharpe , MD;

The no-reflow phenomenon is defined as a severe reduction in antegrade coronary flow in the absence of epicardial vessel obstruction.1 The presence of no-reflow substantially increases the risk of major adverse clinical events (MACE) in...

The no-reflow phenomenon is...

08/01/2008

Journal of Invasive Cardiology

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

See Full Calendar

Douglas Vaughan, MD

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products